Mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer: biological determinants and therapeutic implications
PARP inhibitors have become an integral component of treatment strategies for advanced epithelial ovarian cancer, particularly in BRCA1/2 -mutated and homologous recombination-deficient (HRD) tumors. Despite clinically meaningful improvements in progression-free survival, a substantial proportion of patients develo...